From mutagen hunter to genome defender, a change in paradigm

Mutation Research - Reviews in Mutation Research

Volumn 437, Issue 2, 1999, Pages 113-119

  Rosenkranz, Herbert S ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; ALCOHOL; BETA CAROTENE; CARBON MONOXIDE; DNA; FOOD ADDITIVE; MUTAGENIC AGENT; RESVERATROL; SACCHARIN;

ARTICLE; CANCER INCIDENCE; CARCINOGENESIS; ENVIRONMENTAL PROTECTION; GENETIC TOXICOLOGY; GENOME; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; GENETICS; GENOME; HISTORY, 20TH CENTURY; HUMANS; INDOLES; MUTAGENS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032748335     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(99)00078-2     Document Type: Article

References (71)

1. S. Lewis, Arrowsmith, Harcourt, Brace and Co., New York, 1945.
2. P. de Kruif, Microbe Hunters, Harcourt, Brace and Co., New York, 1953.
3. B. Rouechbe, Eleven Blue Men and Other Narratives of Medical Detection, Little, Brown, Boston, 1953.
4. Slater E.E., Anderson M.D., Rosenkranz H.S. Rapid detection of mutagens and carcinogens. Cancer Res. 31:1971;970-973.
5. Rosenkranz H.S. Aspects of microbiology in cancer research. Ann. Rev. Microbiol. 27:1973;383-401.
6. Higginson J. Present trends in cancer epidemiology. Can. Cancer Conf. 8:1969;40-75.
7. NIEHS, Man's Health and the Environment - Some Research Needs. US Department of Health, Education and Welfare, US Government Printing Office, Washington D.C., 1970.
8. B.N. Ames, The detection of carcinogens as mutagens: The Salmonella/microsome test. In: F.J. De Serres, J.R. Fouts, J.R. Bend, R.M. Philpot (Eds.), In Vitro Metabolic Activation in Mutagenesis Testing, North-Holland Publishing, Amsterdam, The Netherlands, 1976, pp. 57-62.
9. Ames B.N., Durston W.E., Yamasaki E., Lee F.D. Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proc. Nat. Acad. Sci. USA. 70:1973;2281-2285.
10. J.D. Watson, Molecular Biology of the Gene, W.A. Benjamin, New York, NY, 1965.
11. R. Doll, R. Peto, The Causes of Cancer, Oxford Univ. Press, Oxford, 1981.
12. Karp J.E., Chiarodo A., Brawley O., Kelloff G.J. Prostate cancer prevention: investigational approaches and opportunities. Cancer Res. 56:1996;5547-5556.
13. Kelloff G.J., Johnson J.R., Crowell J.A., Boone C.W., DeGeorge J.J., Steele V.E., Mehta M.U., Temeck J.W., Schmidt W.J., Burke G., Greenwald P., Temple R.J. Guidance for development of chemopreventive agents. J. Cell. Biochem. 20:1994;25-31. Suppl.
14. Kelloff G.J., Crowell J.A., Hawk E.T., Steele V.E., Lubet R.A., Boone C.W., Covey J.M., Doody L.A., Omenn G.S., Greenwald P., Hong W.K., Parkinson D.R., Bagheri D., Baxter G.T., Blunden M., Doeltz M.K., Eisenhauer K.M., Johnson K., Knapp G.G., Longfellow D.G., Malone W.F., Nayfield S.G., Seifried H.E., Swall L.M., Sigman C.C. Strategy and planning for chemopreventive drug development: clinical development plans II. J. Cell. Biochem. 26S:1996;54-71.
15. Murakami A., Ohigashi H., Koshimizu K. Anti-tumor promotion with food phytochemicals: a strategy for cancer chemoprevention. Biosci. Biotech. Biochem. 60:1996;1-8.
16. Morse M.A., Stoner G.D. Cancer chemoprevention: principles and prospects. Carcinogenesis. 14:1993;1737-1746.
17. Wattenberg L.W. Prevention of cancer: the role of chemoprevention for the general population and for individuals at high risk due to genetic defects or other factors. Proc. Am. Assoc. Cancer Res. 37:1996;617-618.
18. Dashwood R.H. Letter to the editor. Cancer chemoprevention from the food-borne carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Mutat. Res. 405:1998;109-110.
19. Dashwood R.H. Brief commentary. Indole-3-carbinol: anticarcinogen or tumor promoter in brassica vegetables? Chem.-Biol. Interact. 110:1998;1-5.
20. Kadlubar F.F., Huber W.W. Letter to the editor. Mutat. Res. 405:1998;111-112.
21. Paolini M., Mesirca R., Gialluca N., Bauer C., Biagi G.L., Cantelli-Forti G. On cancer chemoprevention: complications and limitations of some proposed strategies. Carcinogenesis. 16:1995;971-973.
22. Paolini M. Letter to the editor. On the usefulness of drug metabolising enzyme modulation for anti-cancer strategies. Mutat. Res. 405:1998;113-114.
23. R. Pear, US approves drug to help prevent breast cancer in women at risk. New York Times, October 30, 1998.
24. R.A. Merrill, Regulatory toxicology. In: C.D. Klaasson (Ed.), Casarett and Doull's Toxicology, 5th edn., 1996, pp. 1011-1023.
25. HEI, The HEI Multicenter Study Team. Acute effects of carbon monoxide exposure on individuals with coronary artery disease. Health Effects Institute, Cambridge, MA, Research Report No. 25, 1989.
26. US Environmental Protection Agency National Ambient Air Quality Standards for particulate matter: proposed rule. Fed. Reg. 61:1996;65638-65713.
27. US Environmental Protection Agency, Review of the National Ambient Air Quality Standards for Particular Matter: Policy Assessment of Scientific and Technical information (QAPQS Staff Paper). Office of Air Quality Planning and Standards, Research Triangle Park, NC. EPA/452/R-96/013, 1996.
28. McClellan R.O. Testimony on the scientific basis for changes in the National Ambient Air Quality Standards for ozone and particulate matter. CIIT Activities. 17(2):1997;8-12.
29. McClellan R.O., Miller F.J. An overview of EPA's proposed revision of the particular matter standard. CIIT Activities. 17(4):1997;1-22.
30. Vedal S. Ambient particles and health: lines that divide. J. Air Waste Manage. Assoc. 47:1997;551-581.
31. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J., Cullen M.R., Glass A., Keogh J.P., Meyskens F.L. Jr., Valanis B., Williams J.H., Barnhart S., Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334:1996;1150-1155.
32. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J., Cullen M.R., Glass A., Keogh J.P., Meyskens F.L. Jr., Valanis B., Williams J.H. Jr., Barnhart S., Cherniack M.G., Brodkin C.A., Hammar S. Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene and retinol efficacy trial. J. Natl. Can. Inst. 88:1996;1550-1559.
33. Albanes D., Heinonen O.P., Taylor P.R., Virtamo J., Edwards B.K., Rautalahti M., Hartman A.M., Palmgren J., Freedman L.S., Haapakoski J., Barrett M.J., Pietinen P., Malila N., Tala E., Liippo K., Salomaa E.-R., Tangrea J.A., Teppo L., Askin F.B., Taskinen E., Erozan Y., Greenwald P., Huttunen J.K. α-Tocopherol and β-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J. Natl. Cancer Inst. 88:1996;1560-1570.
34. Burton G.W., Ingold K.U. β-Carotene: an unusual type of lipid antioxidant. Science. 234:1984;569-573.
35. Palozza P., Calviello G., Bartoli G.M. Prooxidant activity of β-carotene under 100% oxygen pressure in rat liver microsomes. Free Radical Biol. Med. 19:1995;887-892.
36. Palozza P., Calviello G., Ricci P., Bartoli G.M. Antioxidant and prooxidant role of β-carotene in murine normal and tumor thymocytes: effects of oxygen partial pressure. Free Radical Biol. Med. 22:1997;1065-1073.
37. Omaye S.T., Krinsky N.I., Kagan V.E., Mayne S.T., Liebler D.C., Bidlack W.R. β-Carotene: friend or foe? Fundam. Appl. Toxicol. 40:1997;163-174.
38. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W.W., Fong H.H.S., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 275:1997;218-220.
39. Klopman G., Rosenkranz H.S. Prediction of carcinogenicity/mutagenicity using MULTICASE. Mutat. Res. 305:1994;33-46.
40. Wattenberg L.W., Loub W.D. Inhibition of polycyclic aromatic hydrocarbon induced neoplasia by naturally occurring indoles. Cancer Res. 38:1978;1410-1413.
41. Wong G.Y.C., Bradlow L., Sepkovic D., Mehl S., Mailman J., Osborne M.P. Dose-ranging study of indole-3-carbinol for breast cancer prevention. J. Cell. Biochem. 28-29:1997;111-116. Suppl.
42. Anonymous A clinical development plan: indole-3-carbinol. J. Cell. Biochem. 26:1996;127-136.
43. Michnovicz J.J., Adlercreutz H., Bradlow H.L. Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J. Natl. Cancer Inst. 89:1997;718-723.
44. Cunningham A.R., Rosenkranz H.S., Zhang Y.P., Klopman G. Identification of "genotoxic" and "non-genotoxic" alerts for cancer in mice: the carcinogenicity potency data base. Mutat. Res. 398:1998;1-17.
45. Cunningham A.R., Klopman G., Rosenkranz H.S. Identification of structural features and associated mechanisms of action for carcinogens in rats. Mutat. Res. 405:1998;9-28.
46. Rosenkranz H.S., Klopman G. Structural basis of carcinogenicity in rodents of genotoxicants and non-genotoxicants. Mutat. Res. 228:1990;105-124.
47. Sakai T., Klopman G., Rosenkranz H.S. Structural basis of the induction of pre-neoplastic glutathione-S-transferase positive foci by hepatocarcinogens. Teratog. Carcinog. Mutagen. 14:1994;219-237.
48. O.T. Macina, Y.P. Zhang, H.S. Rosenkranz, Improved predictivity of chemical carcinogens: The use of a battery of SAR Models, in: K.T. Kitchin (Ed.), Carcinogenicity: Testing, Predicting and Interpreting Chemical Effects, Marcel Dekker, New York, 1998, pp. 227-250.
49. Gold L.S., Slone T.H., Ames B.N. What do animal cancer tests tell us about human cancer risk?: overview of analyses of the carcinogenic potency database. Drug Metab. Rev. 30:1998;359-404.
50. Ennever F.K., Noonan T.J., Rosenkranz H.S. The predictivity of animal bioassays and short-term genotoxicity tests for carcinogenicity and non-carcinogenicity to humans. Mutagenesis. 2:1987;73-78.
51. Ashby J., Morrod R.S. Detection of human carcinogens. Nature. 352:1991;185-186.
52. Shelby M.D. The genetic toxicity of human carcinogens and its implications. Mutat. Res. 204:1988;3-15.
53. Bartsch H., Malaveille C. Prevalence of genotoxic chemicals among animal and human carcinogens evaluated in the IARC Monograph Series. Cell Biol. Toxic. 5:1989;115-127.
54. Ashby J., Paton D. The influence of chemical structure on the extent and sites of carcinogenesis for 522 rodent carcinogens and 52 different chemical carcinogen exposures. Mutat. Res. 286:1993;3-74.
55. Rosenkranz H.S., Klopman G. Structural alerts to genotoxicity: the interaction of human and artificial intelligence. Mutagenesis. 5:1990;333-361.
56. Liu M., Sussman N., Klopman G., Rosenkranz H.S. Estimation of the optimal data base size for structure-activity analyses: the Salmonella mutagenicity data base. Mutat. Res. 358:1996;63-72.
57. Zeiger E., Ashby J., Bakale G., Enslein K., Klopman G., Rosenkranz H.S. Prediction of Salmonella mutagenicity. Mutagenesis. 11:1996;471-484.
58. Mersch-Sundermann V., Schneider U., Klopman G., Rosenkranz H.S. SOS-Induction in E. coli and Salmonella mutagenicity: a comparison using 330 compounds. Mutagenesis. 9:1994;205-224.
59. Mersch-Sundermann V., Klopman G., Rosenkranz H.S. Chemical structure and genotoxicity: studies of the SOS chromotest. Mutat. Res. 340:1996;81-91.
60. Zhang Y.P., van Praagh A., Klopman G., Rosenkranz H.S. Structural basis of the induction of unscheduled DNA synthesis in rat hepatocytes. Mutagenesis. 9:1994;141-149.
61. Yotti L.P., Chang C.C., Trosko J.E. Elimination of metabolic cooperation in Chinese hamster cells by a tumor promoter. Science. 206:1979;1089-1091.
62. Murray A.W., Fitzgerald D.J. Tumor promoters inhibit metabolic cooperation in cocultures of epidermal and 3T3 cells. Biochem. Biophys. Res. Commun. 91:1979;395-401.
63. J.E. Trosko, L.P. Yotti, B. Dawson, C.C. Chang, In vitro assay for tumor promoters, in: H.F. Stich, R.H.C. Tan (Eds.), Short-Term Tests for Chemical Carcinogens, Springer, New York, 1980, pp. 420-427.
64. S.H.H. Swierenga, H. Yamasaki, Performance of tests for cell transformation and gap-junction intercellular communication for detecting nongenotoxic carcinogenic activity, in: H. Vainio, P.N. Magee, D.B. McGregor, A.J. McMichael (Eds.), Mechanisms of Carcinogenesis in Risk Identification (Scientific Publication No. 116), International Agency for Research on Cancer, IARC, Lyon, 1992, pp. 165-193.
65. Zeilmaker M.J., Yamasaki H. Inhibition of junctional intercellular communication as a possible short-term test to detect tumor-promoting agents: results with nine chemicals tested by dye transfer assay in Chinese hamster V79 cells. Cancer Res. 46:1986;6180-6186.
66. Rosenkranz M., Rosenkranz H.S., Klopman G. Intercellular communication, tumor promotion and non-genotoxic carcinogenesis: relationships based upon structural considerations. Mutat. Res. 381:1997;171-188.
67. Linkov I., Wilson R., Grey G.M. Anticarcinogenic responses in rodent cancer bioassays are not explained by random effects. Toxicol. Sci. 43:1998;1-9.
68. Chankong V., Haimes Y.Y., Rosenkranz H.S., Pet-Edwards J. The Carcinogenicity Prediction and Battery Selection (CPBS) method: a Bayesian approach. Mutat. Res. 153:1985;135-166.
69. Harris C.C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 88:1996;1442-1455.
70. 1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res. 51:1991;5501-5506.
71. NIEHS (1998) www.niehs.nih.gov/envgenom/home.htonl.